Purine analogs having HSP90-inhibiting activity

Details Purine analogs having HSP90-inhibiting activity Purine analogs having HSP90-inhibiting activity

2007-07-10

2007-07-10

Berch, Mark L. (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Chalcogen bonded directly to ring carbon of the purine ring...

C544S265000, C544S277000

Reexamination Certificate

active

10494414

ABSTRACT:
Novel purine compounds of Formula I.and tautomers, pharmaceutically acceptable salts, and prodrugs thereof, wherein X is S, S(O), or S(O)2; and O is selected from alkyl, cycloalkyl, arylalkyl, aryl, heteroaryl, and heterocyclic, all optionally substituted, are described, as are pharmaceutical compositions comprising the same, complexes comprising the same, e.g., HSP90 complexes, and methods of using the same.

REFERENCES:
patent: 4495190 (1985-01-01), Hagberg et al.
patent: 4547573 (1985-10-01), Jung et al.
patent: 4617304 (1986-10-01), Ashton et al.
patent: 4699877 (1987-10-01), Cline et al.
patent: 4748177 (1988-05-01), Sircar et al.
patent: 4772606 (1988-09-01), Sircar et al.
patent: 4774325 (1988-09-01), Casadio et al.
patent: 4806642 (1989-02-01), Sircar et al.
patent: 4918162 (1990-04-01), Slamon et al.
patent: 4921859 (1990-05-01), Sircar et al.
patent: 4923885 (1990-05-01), Hupe et al.
patent: 4968603 (1990-11-01), Slamon et al.
patent: 5002950 (1991-03-01), Malone et al.
patent: 5098906 (1992-03-01), Sircar et al.
patent: 5110818 (1992-05-01), Allgeier
patent: 5204353 (1993-04-01), Meier
patent: 5217866 (1993-06-01), Summerton et al.
patent: 5332744 (1994-07-01), Chakravarty et al.
patent: 5602156 (1997-02-01), Kohn et al.
patent: 5656629 (1997-08-01), Bacon et al.
patent: 5789394 (1998-08-01), Nguyen-Ba et al.
patent: 5846749 (1998-12-01), Slamon et al.
patent: 5861503 (1999-01-01), Barrio et al.
patent: 5917042 (1999-06-01), Daluge et al.
patent: 5955610 (1999-09-01), Nguyen-Ba et al.
patent: 5994361 (1999-11-01), Penney et al.
patent: 6005107 (1999-12-01), Nguyen-Ba et al.
patent: 6143743 (2000-11-01), Wilde et al.
patent: 6174875 (2001-01-01), DeFranco et al.
patent: 6210974 (2001-04-01), Gold
patent: 6262254 (2001-07-01), Barrio et al.
patent: 6333331 (2001-12-01), Moschel et al.
patent: 6369092 (2002-04-01), Pamukcu et al.
patent: 6723727 (2004-04-01), Peyman et al.
patent: 2002/0156277 (2002-10-01), Fick et al.
patent: 2002/0161014 (2002-10-01), Sadhu et al.
patent: 2003/0022864 (2003-01-01), Ishaq et al.
patent: 2003/0078413 (2003-04-01), Dempcy et al.
patent: 2005/0107343 (2005-05-01), Kasibhatla et al.
patent: 2005/0113339 (2005-05-01), Kasibhatla et al.
patent: 2005/0113340 (2005-05-01), Kasibhatla et al.
patent: 2005/0119282 (2005-06-01), Kasibhatla et al.
patent: 55239 (1982-06-01), None
patent: 156559 (1985-10-01), None
patent: 159264 (1985-10-01), None
patent: 178178 (1986-04-01), None
patent: 206415 (1986-12-01), None
patent: 0184322 (1989-12-01), None
patent: 363320 (1990-04-01), None
patent: 151528 (1990-07-01), None
patent: 465297 (1992-01-01), None
patent: 502690 (1992-09-01), None
patent: 565377 (1993-10-01), None
patent: 675123 (1995-10-01), None
patent: 06080670 (1994-03-01), None
patent: 08041035 (1996-02-01), None
patent: 08208687 (1996-08-01), None
patent: 09020776 (1997-01-01), None
patent: 09169758 2 (1997-06-01), None
patent: 10025294 (1998-01-01), None
patent: 2000-072773 (2000-03-01), None
patent: WO-86/05518 (1986-09-01), None
patent: WO-89/10923 (1989-11-01), None
patent: WO-92/05180 (1992-04-01), None
patent: WO-95/07695 (1995-03-01), None
patent: WO-95/08327 (1995-03-01), None
patent: WO-98/01448 (1998-01-01), None
patent: WO-98/39344 (1998-09-01), None
patent: WO-98/51702 (1998-11-01), None
patent: WO-99/01454 (1999-01-01), None
patent: WO-99/02162 (1999-01-01), None
patent: WO-99/12927 (1999-03-01), None
patent: WO-99/24432 (1999-05-01), None
patent: WO-99/32122 (1999-07-01), None
patent: WO-99/51223 (1999-10-01), None
patent: WO-00/43394 (2000-07-01), None
patent: WO-00/44750 (2000-08-01), None
patent: WO-00/53394 (2000-09-01), None
patent: WO-00/68230 (2000-11-01), None
patent: WO-01/38584 (2001-05-01), None
patent: WO 02/36075 (2002-05-01), None
patent: WO-02/055521 (2002-07-01), None
patent: WO-02/057288 (2002-07-01), None
patent: WO-02/069900 (2002-09-01), None
patent: WO-02/085905 (2002-10-01), None
patent: WO-02/088079 (2002-11-01), None
patent: WO-02/088080 (2002-11-01), None
patent: WO-02/094196 (2002-11-01), None
patent: WO-02/102314 (2002-12-01), None
patent: WO-03/000200 (2003-01-01), None
patent: WO-03/002565 (2003-01-01), None
patent: WO-03/026571 (2003-04-01), None
patent: WO-03/037860 (2003-05-01), None
Janeba, Zlatko, Collection of Czechoslovak Chemical Communications 66(9), 1393-1406 (Sep. 2001).
Panouse, Annales Pharma. Francaises 2000 58(5) 291-302.
Baker et al. “Irreversible Enzyme Inhibitors. XCV. 8-(m-Bromoacetamidobenzylthio) hypoxanthine, and Active-Site-Directed Irreversible Inhibitor of Xanthine Oxidase” J. Medicinal Chemistry 10(4), 682 (1967). See compounds 6, 8a, 12, 14, 15, 17.
Kos et al. “Deamination of 6-Amino-and 6-(Alkylamino)-9-alkylpurines and Demethylation of Methylthiopurines by Sodium in Liquid Ammonia”, J. Org. Chem. 1981, 46, 5000-5003. See Table 1, last 2 compounds.
Noelle et al. “Potential Purine Antagonists. XX. The Preparation and Reactions of Some Methylthiopurines” J. American Chemical Society 81, 5997-6007 (1959). See species of Tables II-IV, Scheme IV.
Van Calenbergh et al. Synthesis and Structure-Activity Relationships of Analogs of 2′-Deoxy-2′-(3-methoxybenzamido)adenosine, a Selective Inhibitor of Trypanosomal Glycosomal Glyceraldehyde-3-phosphate Dehydrogenase J. Med. Chem. 1995, 38, 3838-3849, 1995. See 35a-35b.
U.S. Appl. No. 60/128,593, filed Apr. 9, 1999, Neal Rosen.
U.S. Appl. No. 60/293,246, filed May 23, 2001, Neal Rosen.
U.S. Appl. No. 60/335,391, filed Oct. 30, 2001, Srinivas Kasibhatla.
U.S. Appl. No. 60/371,668, Ulm et al.
Abblard, J. et al., “Preparation et determination de structure de nouvelles pyridines halogenees Mecanisme de l'halagenation,” Bull. Soc. Chim. Fr. 1972, 2466.
Abramovitch Pyridine and its derivatives, Supp. Part 2, Wiley & Sons, 1974, pp. 1-2.
Alhede, J., “A Simple and Efficient Synthesis of 9-Substituted Guanines. Cyclodesulfurization of 1-Substituted-5;[(Thiocarbamoyl)amino]imidazole-4-carboxamides under Aqueous Basic Conditions,” Org. Chem. 1991, 2139.
Andricopulo, A.D. and Yunes, R.A., “Structure-activity relationships for a collection of structurally diverse inhibitors of purine nucleoside phosphorylase,” Chem. & Pharm. Bull. 49(1), 10-17 (2001).
Ashton, W.T. et al., “Synthesis and Antiherpetic Activity of (±)-9-[[(Z)-2-(Hydroxymethyl)cyclopropyl]methyl]guanine and Related Compounds,” J. Med. Chem. 1988, 31, 2304-2315.
Ashwell, M. et al., “An improved route to guanines substituted at N-9,” J. of the Chem. Soc., Chem. Comm. (14), 955-6 (1990).
Bakkestuen, A. K., et al., “9-Benzylpurines with inhibitory activity against Mycobacterium tuberculosis,” Biorg. & Med. Chem. Ltrs., 10(11), 1207-1210 (2000).
Balo, M.C. et al, “Synthesis of novel carbocyclic nucleosides with a cycloopentenyl ring: homocarbovir and analogs,” Tetrahedron 54(12), 2833-2842 (1998).
Balo, M.C. et al, “Synthesis and antiviral activies of some novel carbocyclic nucleosides,” Nucleosides & Nucleotides 15(7&8), 1335-1346 (1996).
Bedard, J. et al., “Comparative study of the anti-human cytomegalovirus activities and toxicities of a tetrahydrofuran phosphonate analog of guanosine and cidofovir,” Antimocrobial Agents & Chemo. 43(3), 557-567 (1999).
Bennett, L.L., et al., “Mode of action of 2-amino-6-chloro-1-deazapurine,” Biochem. Pharmacol. 33(2), 261-71 (1984).
Bennett, S.M., “Synthesis and Antiviral Acitivity of Some Acyclic and C-Acyclic Pyrrolo[2,3-d]pyrimidine Nucleoside Analogues,” J. Med. Chem. 1990, 33, 2162.
Berge et al., “Pharmaceutical Salts,” J. Pharm. Sci. 1977, 66:1-19.
Blanco, J.M. et al., “Synthesis and antiviral and antineoplastic activities of some novel carbocyclic guanosine analogs with a cyclobutane ring,” Chem. & Pharm. Bulletin, 47(9), 1314-1317, (1999).
Blanco, J.M. et al., “Synthesis and antiviral and cytostatic activities of carbocyclic nucleosides ncorporating a modified cyclo

Affiliated with

Also associated with

Rating

Purine analogs having HSP90-inhibiting activity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Purine analogs having HSP90-inhibiting activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Purine analogs having HSP90-inhibiting activity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3753040